In their annual meeting, the World Health Organisation‘s (WHO) Advisory Committee on Safety of Medicinal Products (ACSoMP) once again met to discuss safety issues connected to the medicinal industry.
The ACSoMP meet to provide information and advice to the WHO’s collaborative centres and member states.
Since their last conference, there has been a strengthening in the collaboration between the WHO’s Safety & Vigilance and Disease Control and Treatment Programme teams, with pharmacovigilance at the forefront of the project scope in achieving globalised patient safety.
In order to achieve this, the WHO has enhanced collaboration between member countries; utilising global bench-marking activities and a global comprehensive framework. Altogether, allowing for the assessment and ranking of competency levels for PV systems within member states’ National Regulatory Agencies (NRA’s).
- Outlining of key objectives to achieve global pharmacovigilance
- Bench-marking activities of member states NRA’s
- Innovations in ADR reporting for Burkina Faso, Zambia and 8 other countries
- Support from industry agencies, like the Medicines and Healthcare products Regulatory Agency (MHRA) and European Medicines Agency (EMA)
- Implementation of two pre-qualification pathways
- Creation, utilisation and piloting of a global comprehensive framework underpinned by ranked competencies
Read the full WHO November newsletter hereShare this News item: